Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice
- 8 June 2009
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 119 (7), 2086-2099
- https://doi.org/10.1172/jci34332
Abstract
Liver sinusoidal endothelial cells are a major endogenous source of Factor VIII (FVIII), lack of which causes the human congenital bleeding disorder hemophilia A. Despite extensive efforts, gene therapy using viral vectors has shown little success in clinical hemophilia trials. Here we achieved cell type–specific gene targeting using hyaluronan- and asialoorosomucoid-coated nanocapsules, generated using dispersion atomization, to direct genes to liver sinusoidal endothelial cells and hepatocytes, respectively. To highlight the therapeutic potential of this approach, we encapsulated Sleeping Beauty transposon expressing the B domain–deleted canine FVIII in cis with Sleeping Beauty transposase in hyaluronan nanocapsules and injected them intravenously into hemophilia A mice. The treated mice exhibited activated partial thromboplastin times that were comparable to those of wild-type mice at 5 and 50 weeks and substantially shorter than those of untreated controls at the same time points. Further, plasma FVIII activity in the treated hemophilia A mice was nearly identical to that in wild-type mice through 50 weeks, while untreated hemophilia A mice exhibited no detectable FVIII activity. Thus, Sleeping Beauty transposon targeted to liver sinusoidal endothelial cells provided long-term expression of FVIII, without apparent antibody formation, and improved the phenotype of hemophilia A mice.Keywords
This publication has 79 references indexed in Scilit:
- Phenotypic correction of murine hemophilia A using an iPS cell-based therapyProceedings of the National Academy of Sciences of the United States of America, 2009
- Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortalityJCI Insight, 2008
- Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A miceJCI Insight, 2008
- Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and miceThrombosis Research, 2007
- Nonviral gene delivery: What we know and what is nextThe AAPS Journal, 2007
- Sleeping Beauty Transposase Has an Affinity for Heterochromatin ConformationMolecular and Cellular Biology, 2007
- Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing NanoparticlesBioconjugate Chemistry, 2007
- Emerging vectors and targeting methods for nonviral gene therapyEmerging Drugs, 2006
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003
- Glycosylated Cationic Liposomes for Cell-Selective Gene DeliveryCritical Reviews in Therapeutic Drug Carrier Systems, 2002